Your browser doesn't support javascript.
loading
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Nowicka, Malgorzata; Hilton, Laura K; Ashton-Key, Margaret; Hargreaves, Chantal E; Lee, Chern; Foxall, Russell; Carter, Matthew J; Beers, Stephen A; Potter, Kathleen N; Bolen, Christopher R; Klein, Christian; Knapp, Andrea; Mir, Farheen; Rose-Zerilli, Matthew; Burton, Cathy; Klapper, Wolfram; Scott, David W; Sehn, Laurie H; Vitolo, Umberto; Martelli, Maurizio; Trneny, Marek; Rushton, Christopher K; Slack, Graham W; Farinha, Pedro; Strefford, Jonathan C; Oestergaard, Mikkel Z; Morin, Ryan D; Cragg, Mark S.
Afiliación
  • Nowicka M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Hilton LK; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Ashton-Key M; Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada.
  • Hargreaves CE; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
  • Lee C; Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom.
  • Foxall R; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
  • Carter MJ; Southampton University Hospitals NHS Foundation Trust, Southampton, United Kingdom.
  • Beers SA; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom.
  • Potter KN; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom.
  • Bolen CR; Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton, Faculty of Medicine, Southampton, United Kingdom.
  • Klein C; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
  • Knapp A; Genentech, Inc., South San Francisco, CA.
  • Mir F; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Rose-Zerilli M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Burton C; Royal Marsden Hospital, Sutton, United Kingdom.
  • Klapper W; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
  • Scott DW; St James's Institute of Oncology, Leeds, United Kingdom.
  • Sehn LH; Department of Hematopathology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Vitolo U; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Martelli M; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Trneny M; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Rushton CK; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Slack GW; Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Farinha P; Department of Translational and Precision Medicine, Hematology, Sapienza University, Rome, Italy.
  • Strefford JC; 1st Medical Faculty, Charles University, Prague, Czech Republic; and.
  • Oestergaard MZ; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada; and.
  • Morin RD; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
  • Cragg MS; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Blood Adv ; 5(15): 2945-2957, 2021 08 10.
Article en En | MEDLINE | ID: mdl-34323958
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2021 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2021 Tipo del documento: Article País de afiliación: Suiza